Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PUMA BIOTECHNOLOGY, INC.

Get SEC filing alerts via email and in your feed for PUMA BIOTECHNOLOGY, INC.

PBYI

PUMA BIOTECHNOLOGY, INC.

About PUMA BIOTECHNOLOGY, INC.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative cancer therapies. Its key product, NERLYNX (neratinib), treats HER2-positive breast cancer, while in-licensed alisertib targets Aurora Kinase A for various cancers. The company emphasizes targeted therapies, clinical development, and strategic licensing to address unmet needs in oncology markets worldwide. Its business model combines direct sales, licensing, and partnerships to advance cancer treatment options.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PUMA BIOTECHNOLOGY, INC.

1
1
PUMA BIOTECHNOLOGY, INC. Puma Biotechnology Reports $3.8 Million Net Loss in Q1 2026, Revenue Declines

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
PUMA BIOTECHNOLOGY, INC. Puma Biotechnology Reports $228.4M Revenue and $31.1M Net Income for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
PUMA BIOTECHNOLOGY, INC. Puma Biotechnology Reports $54.5M Revenue in Q3 2025, Down from $80.5M in Q3 2024

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PUMA BIOTECHNOLOGY, INC. Puma Biotechnology Reports $52.4 Million Revenue and $5.9 Million Net Income for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PUMA BIOTECHNOLOGY, INC. Puma Biotechnology Reports $46M Revenue and $3M Net Income in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PUMA BIOTECHNOLOGY, INC. Puma Biotechnology Reports $230.5M Revenue for Fiscal Year 2024, Net Income Increases to $30.3M

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
PUMA BIOTECHNOLOGY, INC. Puma Biotechnology Reports 43% Revenue Growth, Net Income Increase in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments